Create a powerpoint slide from the abstract:

Created using ChatSlide

This project explores a novel approach to reduce Graft-versus-Host Disease (GvHD) in hematopoietic stem cell transplantation (HSCT). It evaluates a calcineurin-free regimen combining sitagliptin and bortezomib in an open-label, multicenter Phase I/II trial. The study aims to improve one-year Graft-versus-Host Disease-Free Survival (GRFS) rates from 30% to 50%, while assessing secondary outcomes such as GVHD incidence, relapse rates, and overall survival. Additionally, it investigates...